Primary Biliary Cholangitis Global Market Opportunities And Strategies To 2034

Description

Primary biliary cholangitis (PBC) is a chronic, progressive liver disease that primarily affects the bile ducts within the liver. It is an autoimmune condition in which the body's immune system mistakenly attacks the small bile ducts, leading to inflammation and scarring. Over time, this damage impairs bile flow, causing a buildup of toxic substances that can lead to liver fibrosis, cirrhosis and ultimately liver failure.

The primary biliary cholangitis market consists of sales by entities (organizations, sole traders and partnerships) of primary biliary cholangitis drugs and treatments that are used to treat PBC. PBC predominantly affects middle-aged women, though it can also occur in men. It is typically diagnosed in individuals between the ages of 40 and 60, often following routine blood tests that indicate liver abnormalities.

The global primary biliary cholangitis market was valued at $733.21 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 5.00%.

Rising Demand for Personalized Medicine

During the historic period, the rising demand for personalized medicine supported the growth of the primary biliary cholangitis market. Personalized medicine tailors treatments based on genetic, molecular and clinical profiles, enabling more precise therapies for primary biliary cholangitis. Obeticholic acid (OCA) serves as a targeted alternative to traditional treatments like ursodeoxycholic acid (UDCA). New therapies, including fibrates and FXR (farnesoid X receptor) agonists, are being evaluated for specific patient groups. Pharmacogenomics enhances treatment by predicting efficacy, minimizing side effects and reducing trial-and-error prescribing. This approach optimizes outcomes by ensuring patients receive the most effective, individualized therapy. For example, in October 2022, the Personalized Medicine Coalition, a US-based organization that represents scientists, patients and providers, promoting the understanding and adoption of personalized medicine to benefit patients and the healthcare system, estimated that more than 75,000 genetic testing products and 300 personalized medicines are on the market for people with multiple types of cancers, genetic rare diseases and a range of chronic and infectious diseases. Additionally, in 2022, according to the Personalized Medicine Coalition (PMC), a US-based company that advocates for personalized medicine, personalized medicines will account for 34% of new drug approvals by the US Food and Drug Administration in 2022 and have accounted for at least 25% of approvals in each of the previous eight years. Therefore, the rising demand for personalized

Role Of Combination Therapy In Liver Disease Management

Major companies operating in the primary biliary cholangitis market are focusing on introducing innovative therapies such as combination therapy to enhance treatment efficacy and improve patient outcomes in liver cancer care. Combination therapy refers to the use of two or more treatments or drugs together to target a specific condition, enhancing the overall therapeutic effect. For example, in June 2024, Ipsen Biopharmaceuticals, Inc., a France-based biopharmaceutical company received U.S. Food and Drug Administration (FDA) approval for Ipsen's Iqirvo (elafibranor) 80 mg (miligram) tablets for treating primary biliary cholangitis (PBC). This drug is a first-in-class PPAR (peroxisome proliferator-activated receptor) treatment. It is intended for use in combination with ursodeoxycholic acid (UDCA) for adults who do not respond adequately to UDCA, or as a monotherapy for patients who cannot tolerate UDCA.

The global primary biliary cholangitis market is highly concentrated, with large players operating in the market. The top ten competitors in the market made up to 50.90% of the total market in 2023.

Primary Biliary Cholangitis Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global primary biliary cholangitis market as it emerges from the COVID-19 shut down.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for primary biliary cholangitis? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The primary biliary cholangitis market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider primary biliary cholangitis market; and compares it with other markets.

The report covers the following chapters

Introduction And Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by treatment type, by diagnosis and by end user.
Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
Growth Analysis And Strategic Analysis Framework- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by treatment type, by diagnosis and by end user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by exchange model, by trading type, by coin or token and by payment method in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
Regional Market Size And Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
Competitive Dashboard- Briefs on competitive dashboard of major players.
Key Mergers And Acquisitions- Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
Recent Developments- Information on recent developments in the market covered in the report.
Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
Conclusions And Recommendations- This section includes recommendations for primary biliary cholangitis providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

1) By Treatment Type: Drugs; Liver Transplantation
2)By Diagnosis: Magnetic Resonance Elastography (MRE); Magnetic Resonance Cholangiopancreatography (MRCP); Ultrasound; Fibroscan; Cholesterol Test; Antibody Tests; Liver Tests; Other Diagnoses
3) By End User: Hospitals; Specialty Clinics; Homecare; Other End-Users
Companies Mentioned: Intercept Pharmaceuticals Inc.; Mayo Clinic Laboratories; University of Pittsburgh Medical Center (UPMC); Stanford Health Care; Duke University Hospital
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia; Africa
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time-series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; primary biliary cholangitis indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Product Code: o&s1561

1 Executive Summary

1.1 Primary Biliary Cholangitis - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

6.1 General Market Definition
6.2 Summary
6.3 Primary Biliary Cholangitis Market Definition And Segmentations
6.4 Market Segmentation By Treatment Type
- 6.4.1 Drugs
- 6.4.2 Liver Transplantation
6.5 Market Segmentation By Diagnosis
- 6.5.1 Magnetic Resonance Elastography (MRE)
- 6.5.2 Magnetic Resonance Cholangiopancreatography (MRCP)
- 6.5.3 Ultrasound
- 6.5.4 Fibroscan
- 6.5.5 Cholesterol Test
- 6.5.6 Antibody Tests
- 6.5.7 Liver Tests
- 6.5.8 Other Diagnoses
6.6 Market Segmentation By End User
- 6.6.1 Hospitals
- 6.6.2 Specialty Clinics
- 6.6.3 Homecare
- 6.6.4 Other End-Users

7 Major Market Trends

7.1 Role Of Combination Therapy In Liver Disease Management
7.2 Advancements In Bile Acid Analog-Based Therapies
7.3 Strategic Partnerships Driving Innovation In PBC Treatment

8 Global Primary Biliary Cholangitis Growth Analysis And Strategic Analysis Framework

8.1 Global Primary Biliary Cholangitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 8.1.1 Political
- 8.1.2 Economic
- 8.1.3 Social
- 8.1.4 Technological
- 8.1.5 Environmental
- 8.1.6 Legal
8.2 Analysis Of End Use Industries
- 8.2.1 Hospitals And Specialty Clinics
- 8.2.2 Homecare
- 8.2.3 Diagnostic Laboratories
- 8.2.4 Pharmaceutical & Biotechnology Companies
- 8.2.5 Other End Users
8.3 Global Primary Biliary Cholangitis Market Growth Rate Analysis
8.4 Historic Market Growth, 2019 - 2024, Value ($ Million)
- 8.4.1 Market Drivers 2019 - 2024
- 8.4.2 Market Restraints 2019 - 2024
8.5 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
- 8.5.1 Market Drivers 2024 - 2029
- 8.5.2 Market Restraints 2024 - 2029
8.6 Forecast Growth Contributors/Factors
- 8.6.1 Quantitative Growth Contributors
- 8.6.2 Drivers
- 8.6.3 Restraints
8.7 Global Primary Biliary Cholangitis Total Addressable Market (TAM)

9 Global Primary Biliary Cholangitis Market Segmentation

9.1 Global Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.2 Global Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.3 Global Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.4 Global Primary Biliary Cholangitis Market, Sub-Segmentation Of Drugs, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.5 Global Primary Biliary Cholangitis Market, Sub-Segmentation By Liver Transplantation, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

10 Primary Biliary Cholangitis Market, Regional and Country Analysis

10.1 Global Primary Biliary Cholangitis Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
10.2 Global Primary Biliary Cholangitis Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Asia-Pacific Market

11.1 Summary
11.2 Market Overview
- 11.2.1 Region Information
- 11.2.2 Market Information
- 11.2.3 Background Information
- 11.2.4 Government Initiatives
- 11.2.5 Regulations
- 11.2.6 Regulatory Bodies
- 11.2.7 Major Associations
- 11.2.8 Taxes Levied
- 11.2.9 Corporate Tax Structure
- 11.2.10 Investments
- 11.2.11 Major Companies
11.3 Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.4 Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.5 Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.6 Asia-Pacific Primary Biliary Cholangitis Market: Country Analysis
11.7 China Market
11.8 Summary
11.9 Market Overview
- 11.9.1 Country Information
- 11.9.2 Market Information
- 11.9.3 Background Information
- 11.9.4 Government Initiatives
- 11.9.5 Regulations
- 11.9.6 Regulatory Bodies
- 11.9.7 Major Associations
- 11.9.8 Taxes Levied
- 11.9.9 Corporate Tax Structure
- 11.9.10 Investments
- 11.9.11 Major Companies
11.10 China Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.11 China Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.12 China Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.13 India Market
11.14 India Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.15 India Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.16 India Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.17 Japan Market
11.18 Summary
11.19 Market Overview
- 11.19.1 Country Information
- 11.19.2 Market Information
- 11.19.3 Background Information
- 11.19.4 Government Initiatives
- 11.19.5 Regulations
- 11.19.6 Regulatory Bodies
- 11.19.7 Major Associations
- 11.19.8 Taxes Levied
- 11.19.9 Corporate Tax Structure
- 11.19.10 Major Companies
11.20 Japan Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.21 Japan Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.22 Japan Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.23 Australia Market
11.24 Australia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.25 Australia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.26 Australia Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.27 Indonesia Market
11.28 Indonesia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.29 Indonesia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.30 Indonesia Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.31 South Korea Market
11.32 Summary
11.33 Market Overview
- 11.33.1 Country Information
- 11.33.2 Market Information
- 11.33.3 Background Information
- 11.33.4 Government Initiatives
- 11.33.5 Regulations
- 11.33.6 Regulatory Bodies
- 11.33.7 Major Associations
- 11.33.8 Taxes Levied
- 11.33.9 Corporate Tax Structure
- 11.33.10 Major Companies
11.34 South Korea Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.35 South Korea Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.36 South Korea Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Western Europe Market

12.1 Summary
12.2 Market Overview
- 12.2.1 Region Information
- 12.2.2 Market Information
- 12.2.3 Background Information
- 12.2.4 Government Initiatives
- 12.2.5 Regulations
- 12.2.6 Regulatory Bodies
- 12.2.7 Major Associations
- 12.2.8 Taxes Levied
- 12.2.9 Corporate tax structure
- 12.2.10 Investments
- 12.2.11 Major Companies
12.3 Western Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.4 Western Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.5 Western Europe Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.6 Western Europe Primary Biliary Cholangitis Market: Country Analysis
12.7 UK Market
12.8 UK Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.9 UK Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.10 UK Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.11 Germany Market
12.12 Germany Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.13 Germany Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.14 Germany Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.15 France Market
12.16 France Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.17 France Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.18 France Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.19 Italy Market
12.20 Italy Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.21 Italy Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.22 Italy Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.23 Spain Market
12.24 Spain Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.25 Spain Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.26 Spain Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Eastern Europe Market

13.1 Summary
13.2 Market Overview
- 13.2.1 Region Information
- 13.2.2 Market Information
- 13.2.3 Background Information
- 13.2.4 Government Initiatives
- 13.2.5 Regulations
- 13.2.6 Regulatory Bodies
- 13.2.7 Major Associations
- 13.2.8 Taxes Levied
- 13.2.9 Corporate Tax Structure
- 13.2.10 Major companies
13.3 Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.4 Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.5 Eastern Europe Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.6 Eastern Europe Primary Biliary Cholangitis Market: Country Analysis
13.7 Russia Market
13.8 Russia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.9 Russia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.10 Russia Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 North America Market

14.1 Summary
14.2 Market Overview
- 14.2.1 Region Information
- 14.2.2 Market Information
- 14.2.3 Background Information
- 14.2.4 Government Initiatives
- 14.2.5 Regulations
- 14.2.6 Regulatory Bodies
- 14.2.7 Major Associations
- 14.2.8 Taxes Levied
- 14.2.9 Corporate Tax Structure
- 14.2.10 Investments
- 14.2.11 Major Companies
14.3 North America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.4 North America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.5 North America Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.6 North America Primary Biliary Cholangitis Market: Country Analysis
14.7 USA Market
14.8 Summary
14.9 Market Overview
- 14.9.1 Country Information
- 14.9.2 Market Information
- 14.9.3 Background Information
- 14.9.4 Government Initiatives
- 14.9.5 Regulations
- 14.9.6 Regulatory Bodies
- 14.9.7 Major Associations
- 14.9.8 Taxes Levied
- 14.9.9 Corporate Tax Structure
- 14.9.10 Investments
- 14.9.11 Major Companies
14.10 USA Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.11 USA Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.12 USA Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.13 Canada Market
14.14 Summary
14.15 Market Overview
- 14.15.1 Country Information
- 14.15.2 Market Information
- 14.15.3 Background Information
- 14.15.4 Government Initiatives
- 14.15.5 Regulations
- 14.15.6 Regulatory Bodies
- 14.15.7 Major Associations
- 14.15.8 Taxes Levied
- 14.15.9 Corporate Tax Structure
- 14.15.10 Major Companies
14.16 Canada Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.17 Canada Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.18 Canada Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 South America Market

15.1 Summary
15.2 Market Overview
- 15.2.1 Region Information
- 15.2.2 Market Information
- 15.2.3 Background Information
- 15.2.4 Government Initiatives
- 15.2.5 Regulations
- 15.2.6 Regulatory Bodies
- 15.2.7 Major Associations
- 15.2.8 Taxes Levied
- 15.2.9 Corporate Tax Structure
- 15.2.10 Investments
- 15.2.11 Major Companies
15.3 South America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.4 South America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.5 South America Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.6 South America Primary Biliary Cholangitis Market: Country Analysis
15.7 Brazil Market
15.8 Brazil Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.9 Brazil Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.10 Brazil Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 Middle East Market

16.1 Summary
16.2 Market Overview
- 16.2.1 Region Information
- 16.2.2 Market Information
- 16.2.3 Background Information
- 16.2.4 Government Initiatives
- 16.2.5 Regulations
- 16.2.6 Regulatory Bodies
- 16.2.7 Major Associations
- 16.2.8 Taxes Levied
- 16.2.9 Corporate Tax Structure
- 16.2.10 Major Companies
16.3 Middle East Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.4 Middle East Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.5 Middle East Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Africa Market

17.1 Summary
17.2 Market Overview
- 17.2.1 Region Information
- 17.2.2 Market Information
- 17.2.3 Background Information
- 17.2.4 Government Initiatives
- 17.2.5 Regulations
- 17.2.6 Regulatory Bodies
- 17.2.7 Major Associations
- 17.2.8 Taxes Levied
- 17.2.9 Corporate Tax Structure
- 17.2.10 Major Companies
17.3 Africa Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17.4 Africa Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17.5 Africa Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 Competitive Landscape and Company Profiles

18.1 Company Profiles
18.2 Intercept Pharmaceuticals Inc.
- 18.2.1 Company Overview
- 18.2.2 Products And Services
- 18.2.3 Business Strategy
- 18.2.4 Financial Overview
18.3 Mayo Clinic Laboratories
- 18.3.1 Company Overview
- 18.3.2 Products And Services
- 18.3.3 Business Strategy
- 18.3.4 Financial Overview
18.4 University of Pittsburgh Medical Center (UPMC)
- 18.4.1 Company Overview
- 18.4.2 Products And Services
- 18.4.3 Financial Overview
18.5 Stanford Health Care
- 18.5.1 Company Overview
- 18.5.2 Products And Services
- 18.5.3 Financial Overview
18.6 Duke University Hospital
- 18.6.1 Company Overview
- 18.6.2 Products And Services
- 18.6.3 Financial Overview

19 Other Major And Innovative Companies

19.1 UCLA Medical Center
- 19.1.1 Company Overview
- 19.1.2 Products and Services
19.2 King's College Hospital
- 19.2.1 Company Overview
- 19.2.2 Products and Services
19.3 NewYork-Presbyterian Hospital
- 19.3.1 Company Overview
- 19.3.2 Products and Services
19.4 Cleveland Clinic
- 19.4.1 Company Overview
- 19.4.2 Products and Services
19.5 Johns Hopkins Hospital
- 19.5.1 Company Overview
- 19.5.2 Products and Services
19.6 GENFIT S.A
- 19.6.1 Company Overview
- 19.6.2 Products and Services
19.7 Ipsen Pharma SA
- 19.7.1 Company Overview
- 19.7.2 Products and Services
19.8 Gilead Sciences Inc.
- 19.8.1 Company Overview
- 19.8.2 Products and Services
19.9 Ascletis Pharma Inc.
- 19.9.1 Company Overview
- 19.9.2 Products and Services
19.10 Calliditas Therapeutics AB
- 19.10.1 Company Overview
- 19.10.2 Products and Services
19.11 Cour Pharmaceutical
- 19.11.1 Company Overview
- 19.11.2 Products and Services
19.12 GlaxoSmithKline plc (GSK)
- 19.12.1 Company Overview
- 19.12.2 Products and Services
19.13 HighTide Biopharma Inc.
- 19.13.1 Company Overview
- 19.13.2 Products and Services
19.14 Mirum Pharmaceuticals Inc.
- 19.14.1 Company Overview
- 19.14.2 Products and Services
19.15 NGM Biopharmaceuticals Inc.
- 19.15.1 Company Overview
- 19.15.2 Products and Services

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

22.1 Gilead Sciences Acquired CymaBay Therapeutics
22.2 Alfasigma Acquired Intercept Pharmaceuticals
22.3 Ipsen Acquired Albireo Pharma
22.4 Advanz Pharma Corp. Limited Acquired Intercept Pharmaceuticals

23 Recent Development In Primary Biliary Cholangitis Market

23.1 Orphan Drug Designation To CNP-104 For Primary Biliary Cholangitis
23.2 FDA Grants Accelerated Approval To Seladelpar For Primary Biliary Cholangitis

24 Opportunities And Strategies

24.1 Global Primary Biliary Cholangitis Market In 2029 - Countries Offering Most New Opportunities
24.2 Global Primary Biliary Cholangitis Market In 2029 - Segments Offering Most New Opportunities
24.3 Global Primary Biliary Cholangitis Market In 2029 - Growth Strategies
- 24.3.1 Market Trend Based Strategies
- 24.3.2 Competitor Strategies

25 Primary Biliary Cholangitis Market, Conclusions And Recommendations

25.1 Conclusions
25.2 Recommendations
- 25.2.1 Product
- 25.2.2 Place
- 25.2.3 Price
- 25.2.4 Promotion
- 25.2.5 People

26 Appendix

26.1 Geographies Covered
26.2 Market Data Sources
26.3 Research Methodology
26.4 Currencies
26.5 The Business Research Company
26.6 Copyright and Disclaimer